LRMR News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

LR

Mkt Cap

$206.2M

Volume

1.49M

Next Earnings

November 4th

Loading chart

LR

LRMRLarimar Therapeutics, Inc. Common Stock

LRMR

Pay with—

Available Balance0.00

LR

Mkt Cap

$206.7M

Volume

1.49M

Next Earnings

November 4th

Chart Financials Earnings News About Insider Filings

Larimar (LRMR) Loses 22.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerLarimar stock has declined 22.7% over the past four weeks and is now in oversold territory with an RSI reading of 28.31, suggesting a potential trend reversal. Analysts have raised earnings estimates by 5% over the last 30 days, and the stock holds a Zacks Rank #2 (Buy) rating, indicating potential near-term price appreciation.Zacks Investment Research · Oct 5, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMRPomerantz LLP is investigating potential securities fraud claims against Larimar Therapeutics regarding its nomlabofusp drug candidate for Friedreich's Ataxia. The company's stock fell significantly after disclosing serious safety concerns—anaphylaxis in 7 participants in September 2025 and in 10 of 43 patients by June 2026—despite characterizing the data as 'positive' in press releases.GlobeNewswire Inc. · Jul 7, 2026

Larimar Therapeutics Announces Pricing of Upsized $100 Million Underwritten Public OfferingLarimar Therapeutics (NASDAQ: LRMR), a clinical-stage biotechnology company, announced the pricing of an upsized underwritten public offering of 20 million shares at $5.00 per share, generating $100 million in gross proceeds. The offering is expected to close on February 27, 2026, with proceeds to be used for development of nomlabofusp and general corporate purposes. J.P. Morgan and Guggenheim Securities are serving as joint bookrunning managers.Benzinga · Feb 26, 2026

Larimar Therapeutics Announces Pricing of Upsized $100 Million Underwritten Public OfferingLarimar Therapeutics priced an upsized underwritten public offering of 20 million shares at $5.00 per share, generating $100 million in gross proceeds. The company plans to use the funds to support development of nomlabofusp for Friedreich's ataxia and for general corporate purposes. The offering is expected to close on February 27, 2026, with J.P. Morgan and Guggenheim Securities as joint bookrunning managers.GlobeNewswire Inc. · Feb 26, 2026

Larimar Therapeutics, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - LRMRDJS Law Group is investigating Larimar Therapeutics for potential securities law violations after a clinical study revealed severe allergic reactions, causing the company's stock to drop 33.66%.Benzinga · Oct 16, 2025

Larimar Therapeutics, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – LRMRDJS Law Group is investigating Larimar Therapeutics for potential securities law violations after a clinical study revealed severe allergic reactions, causing the company's stock to drop 33.66%.Benzinga · Oct 16, 2025

LRMR Investors Have Opportunity to Join Larimar Therapeutics, Inc. Fraud Investigation with the Schall Law FirmThe Schall Law Firm is investigating potential securities law violations by Larimar Therapeutics after the company reported study data with severe allergic reactions, causing a significant stock price drop.Benzinga · Oct 16, 2025

Larimar Therapeutics Stock Falls After Patients Report Allergic Reaction In Pivotal StudyLarimar Therapeutics reported allergic reactions in a pivotal study for nomlabofusp, a treatment for Friedreich's ataxia. Seven participants experienced anaphylaxis, leading to study modifications and stock price decline.Benzinga · Sep 29, 2025

Larimar Therapeutics Announces Positive Data from Ongoing Long-term Open Label Study and Updates to Nomlabofusp Program for Friedreich’s AtaxiaLarimar Therapeutics reported positive results from its ongoing study of nomlabofusp, a potential treatment for Friedreich's Ataxia, showing increased frataxin levels and potential clinical improvements, despite experiencing some anaphylaxis events.GlobeNewswire Inc. · Sep 29, 2025

Larimar Therapeutics Announces Conference Call on the Nomlabofusp Program for the Treatment of Friedreich’s AtaxiaLarimar Therapeutics will host a conference call to discuss updates on its nomlabofusp clinical development program for treating Friedreich's ataxia, sharing data from an ongoing long-term open label study.GlobeNewswire Inc. · Sep 28, 2025

to start trading

LR

LRMRLarimar Therapeutics, Inc. Common Stock

LRMR

Pay with—

Available Balance0.00

Your PositionYou don't own any LRMR yet.

Related Tickers

Earnings